Peter Marek

Director, Antibody Discovery at Tectonic Therapeutic

Peter Marek has worked for four different companies since 2006. Peter began their career as a Teaching Assistant at Stony Brook University, Department of Chemistry in 2006. From 2012 to 2018, they were a Postdoctoral Research Fellow at the University of Texas at Austin, where they focused on utilizing directed evolution, novel high-throughput yeast display screening technologies and next-generation sequencing to engineer enzymes. In 2018, they became a Scientist II at Elstar Therapeutics Inc. and in 2020, they were promoted to Principal Scientist and then Senior Scientist at Tectonic Therapeutic, Inc.

Peter Marek earned a B.S. in Biochemistry from Stony Brook University in 2006, graduating Cum Laude. Peter then continued their studies at Stony Brook University, earning a PhD in Chemistry in 2012.

Location

Boston, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Tectonic Therapeutic

5 followers

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs).


Industries

Employees

51-200

Links